<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690079</url>
  </required_header>
  <id_info>
    <org_study_id>D5090C00008</org_study_id>
    <secondary_id>EudraCT No. 2007-005470-31</secondary_id>
    <nct_id>NCT00690079</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386</brief_title>
  <acronym>MAD</acronym>
  <official_title>A Phase I, Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1386 in Healthy Caucasian Young and Elderly Subjects After Oral Multiple Doses.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being performed in order to learn more about the safety and tolerability of
      AZD1386. AZD1386 is primary intended for treatment of chronic pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety AEs and vital signs</measure>
    <time_frame>During the whole study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG-recordings</measure>
    <time_frame>ECGs (5 minutes) Days 1 and 12. 2 ECGs (5 minutes) Days 3, 6 and 10. 1 ECG (5 minutes) Days 2 and 13.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK</measure>
    <time_frame>Days 1, 5 and 12, 12 times each day. Days 4, 6, 8, 10 and 14, once. Days 2, 3, 7, 9, 11 and 13 twice.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>AZD1386</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 groups receiving a specified volume of the active component AZD1386 at different points of time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>7 groups receiving a specified volume of placebo at different points of time</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1386</intervention_name>
    <description>Oral admin. of doses at 11 days through a 12 days period. Cmax = 16 mikromol/L and AUCmax = 98 mikromol*h/L</description>
    <arm_group_label>AZD1386</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral admin. of doses at 11 days through a 12 days period.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Caucasians, males or females aged ≥20 and ≤ 45 years or between 65 80 years.
             Female subjects must be surgically sterile or post-menopausal for at least 12 months
             prior to the enrolment visit.

          -  Body Mass Index (BMI) of ≥18 to ≤ 30 kg/m2 and weight of ≥50 to ≤100 kg

          -  Clinically normal physical findings including heart rate &gt; 45 bpm and laboratory
             values and normal resting ECG

        Exclusion Criteria:

          -  History of somatic or psychiatric disease/condition, which may interfere with the
             objectives of the study.

          -  History of severe allergy/hypersensitivity or symptoms/signs of ongoing
             allergy/hypersensitivity.

          -  Subjects with a high decrease in blood pressure within 5 minutes when going from a
             supine to standing position.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Karlsten</last_name>
    <role>Study Director</role>
    <affiliation>Emerging Analgesia TA AstraZeneca R&amp;D Södertälje, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ray Chetty</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca Alderly Park1G61 Mereside, Alderly Park, Macclesfeld, Cheshire, England SK104TG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Macclesfield</city>
        <state>Cheshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <last_update_submitted>December 8, 2010</last_update_submitted>
  <last_update_submitted_qc>December 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Rolf Karlsten, MD, PhD Medical Science Director</name_title>
    <organization>AstraZeneca R&amp;D Södertälje SE-151 85 Södertälje, Sweden</organization>
  </responsible_party>
  <keyword>MAD</keyword>
  <keyword>Multiple ascending dose</keyword>
  <keyword>Chronic pain</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

